|
Abstract:
|
An immune response as correlate of protection (CoP) is of great value in vaccine development. It can be used to aid development of new vaccine, assess consistency of vaccine manufacturing process, or bridge vaccine formulations. Thus, it is desirable to establish a CoP for an Ebola vaccine. However, the vaccine presents a unique challenge; no study so far was able to collect both Ebola disease status and immune response together from human subjects to allow a direct analysis of immune response and disease status. This presentation will explore methods using non-human primes (NHP) to establish a CoP and bridge from NHP to human to estimate vaccine's efficacy in human.
|
